• 2022年度
• 2021年度
• 2020年度
• 2019年度
• 2018年度
• 2017年度
• 2016年度
• 2015年度
• 2014年度
• 2013年度

2015年度論文業績

• Arai Y, Takeda J, Aoki K, Kondo T, Takahashi S, Onishi Y, Ozawa Y, Aotsuka N, Kouzai Y, Nakamae H, Ota S, Nakaseko C, Yamaguchi H, Kato K, Atsuta Y, Takami A; AML and MDS Working Group of the Japan Society for Hematopoietic Cell Transplantation. Efficiency of high-dose cytarabine added to CY/TBI in cord blood transplantation for myeloid malignancy. Blood. 2015;126(3):415-422.
• Nei T, Sonobe K, Onodera A, Itabashi T, Yamaguchi H, Maeda M, Saito R. Two cases with bacteremia suspected to be due to relatively rare Pseudomonas (Flavimonas) oryzihabitans. J Infect Chemother. 2015;21(10):751-755.
• Watanabe E, Nishikawa T, Ikawa K, Yamaguchi H, Abematsu T, Nakagawa S, Kurauchi K, Kodama Y, Tanabe T, Shinkoda Y, Matsumoto K, Okamoto Y, Takeda Y, Kawano Y. Trough level monitoring of intravenous busulfan to estimate the area under the plasma drug concentration-time curve in pediatric hematopoietic stem cell transplant recipients. Int J Hematol. 2015;102(5):611-616.
• Yamaguchi H, Sakaguchi H, Yoshida K, Yabe M, Yabe H, Okuno Y, Muramatsu H, Takahashi Y, Yui S, Shiraishi Y, Chiba K, Tanaka H, Miyano S, Inokuchi K, Ito E, Ogawa S, Kojima S. The clinical and genetic features of dyskeratosis congenita, cryptic dyskeratosis congenita, and Hoyeraal-Hreidarsson syndrome in Japan. Int J Hematol. 2015;102(5):544-552.
• Garg M, Nagata Y, Kanojia D, Mayakonda A, Yoshida K, Haridas Keloth S, Zang ZJ, Okuno Y, Shiraishi Y, Chiba K, Tanaka H, Miyano S, Ding LW, Alpermann T, Sun QY, Lin DC, Chien W, Madan V, Liu LZ, Tan KT, Sampath A, Venkatesan S, Inokuchi K, Wakita S, Yamaguchi H, Chng WJ, Kham SK, Yeoh AE, Sanada M, Schiller J, Kreuzer KA, Kornblau SM, Kantarjian HM, Haferlach T, Lill M, Kuo MC, Shih LY, Blau IW, Blau O, Yang H, Ogawa S, Koeffler HP. Integrative and Comparative Genomic Analysis of Acute Myeloid Leukemia, FLT3-ITD Subgroup at both Diagnosis and Relapse. Blood. 2015;126(22):2491-2501.
• Yui S, Yamaguchi H, Imadome K, Arai A, Takahashi M, Ohashi R, Tamai H, Moriya K, Nakayama K, Shimizu A, Inokuchi K. Epstein-Barr virus-positive T cell lymphoproliferative disease following umbilical cord blood transplantation for acute myeloid leukemia. J Nippon Med Sch. 2016;83(1):35-42.
• Wakita S, Yamaguchi H, Ueki T, Usuki K, Kurosawa S, Kobayashi Y, Kawata E, Tajika K, Gomi S, Koizumi M, Fujiwara Y, Yui S, Fukunaga K, Ryotokuji T, Hirakawa T, Arai K, Kitano T, Kosaka F, Tamai H, Nakayama K, Fukuda T, Inokuchi K. Complex genetic abnormalities involving three or more genetic mutations are important prognostic factors for acute myeloid leukemia. Leukemia. 2016;30(3):545-554.
• Okabe M, Yamaguchi H, Usuki K, Kobayashi Y, Kawata E, Kuroda J, Kimura S, Tajika K, Gomi S, Arima N, Mori S, Ito S, Koizumi M, Ito Y, Wakita S, Arai K, Kitano T, Kosaka F, Dan K, Inokuchi K. Clinical features of Japanese polycythemia vera and essential thrombocythemia patients harboring CALR, JAK2V617F, JAK2Ex12del, and MPLW515L/K mutations. Leuk Res. 2016;40:68-76.
• Tamai H, Yamanaka S, Yamaguchi H, Nakayama K, Inokuchi K. Effective Management of Acute Promyelocytic Leukemia with High Risk of Fatal Intracranial Hemorrhage. Bio Med.2015,8:1
• Inami T, Okabe M, Matsushita M, Kobayashi N, Inokuchi K, Hata N, Seino Y, Shimizu W. JAK2 mutation and acute coronary syndrome complicated with stent thrombosis. Heart Vessels. 2016 Jan 29.
• Isono N, Imai Y, Watanabe A, Moriya K, Tamura H, Inokuchi K, Asano C, Masuda M, Shimura H, Mitsuhashi K, Kazama H, Sugimori H, Motoji T, Tanaka J. Cytomegalovirus reactivation in low-grade B-cell lymphoma patients treated with bendamustine. Leuk Lymphoma. 2015. 24:1-4.
• Iriyama N, Fujisawa S, Yoshida C, Wakita H, Chiba S, Okamoto S, Kawakami K, Takezako N, Kumagai T, Inokuchi K, Ohyashiki K, Taguchi J, Yano S, Igarashi T, Kouzai Y, Morita S, Sakamoto J, Sakamaki H. Early cytotoxic lymphocyte expansion contributes to a deep molecular response to dasatinib in patients with newly diagnosed chronic myeloid leukemia in the chronic phase: results of the D-first study. Am J Hematol. 2015;90(9):819-824.
• Iriyama N, Fujisawa S, Yoshida C, Wakita H, Chiba S, Okamoto S, Kawakami K, Takezako N, Kumagai T, Inokuchi K, Ohyashiki K, Taguchi J, Yano S, Igarashi T, Kouzai Y, Morita S, Sakamoto J, Sakamaki H. Shorter halving time of BCR-ABL1 transcripts is a novel predictor for achievement of molecular responses in newly diagnosed chronic-phase chronic myeloid leukemia treated with dasatinib: Results of the D-first study of Kanto CML study group. Am J Hematol. 2015;90(4):282-287.